New & Notable
AstraZeneca joins Pfizer in most-favored nation pricing program
AstraZeneca joins Pfizer in the White House's most favored nation drug pricing program, expanding TrumpRx's reach but raising questions about real-world savings.
GLP-1 drugs can interfere with FDG-PET-CT scans, study says
Taking GLP-1 receptor agonists can cause atypical tracer uptake patterns in the body that could be mistaken for inflammation or cancer in FDG-PET-CT scans.
Amazon Pharmacy debuts drug-dispensing kiosks at One Medical
Amazon Pharmacy will install drug-dispensing kiosks at select One Medical offices in Los Angeles beginning in December, with plans to expand outside California in 2026.
Survey: Pharmacists overwhelmed by volume over value
Most pharmacists feel overwhelmed by competing job demands, which limit patient-centered care for those managing diabetes, a new CCS report finds.
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
FDA cracks down on online advertising of compounded GLP-1 drugs
More than 50 digital health providers were sent FDA warning letters for falsely advertising compounded GLP-1 drugs. Now, companies must update product information or face legal action.
-
Generic, biosimilar markets at risk despite saving $467B in 2024
Generics and biosimilars cut U.S. drug costs by $467B in 2024, but the AAM warns that PBMs, IRA rules and a lack of competition threaten long-term stability of the market.
-
What the FDA's DTC drug ad crackdown means for pharma companies
As the FDA and HHS rein in direct-to-consumer drug advertising, new compliance rules and AI-driven monitoring could require some pharma companies to rethink their marketing approach.
-
Elsevier launches PharmaPendium AI to boost R&D, compliance
Elsevier debuts PharmaPendium AI, a GenAI tool that helps regulatory, preclinical and clinical teams access FDA, EMA and other regulatory data to accelerate R&D and compliance.
-
CDC Director fired as FDA restricts COVID-19 vaccine use
CDC Director Susan Monarez was fired the same day the FDA rescinded emergency use authorizations for COVID-19 vaccines, restricting use for seniors and high-risk younger people.
-
Lilly eyes FDA review after oral GLP-1 weight loss trial
Eli Lilly's daily oral GLP-1, orforglipron, led to weight loss and improved glycemic control in a Phase 3 trial, setting it up for FDA review and competition with oral Wegovy.
Features
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.
-
Exploring Red No. 3 ban reformulation strategies for Rx, OTC drugs
By Jan. 15, 2028, drug makers must rethink their approach to excipients, stability and color strategy to remove Red No. 3 from ingested prescription and over-the-counter products.
-
Understanding the importance of randomized clinical trials
Randomized controlled trials are the gold standard for proving therapeutic value, drug safety and efficacy, shaping pricing, reimbursement and securing regulatory approval.